Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ST 501

Next Previous
Search
Drug Profile

ST 501

Alternative Names: ST-501; Tau targeting ZFP TF-Sangamo Therapeutics

Latest Information Update: 18 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sangamo Therapeutics
  • Developer Biogen; Sangamo Therapeutics
  • Class Antidementias; Gene therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Genetic transcription inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 13 Mar 2024 Sangamo Therapeutics intends to submit an IND application to the US FDA for Alzheimer’s disease in the fourth quarter of 2025
  • 29 Feb 2024 Preclinical trials in Alzheimer's disease in USA (IV) (Sangamo Therapeutics Pipeline, February 2024)
  • 15 May 2023 Discontinued - Preclinical for Alzheimer's disease in USA (IV) (Sangamo Therapeutics pipeline; May 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top